Dr. Reddy’s Announces the Launch of Decitabine for Injection
HYDERABAD, India -- July 12, 2013
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched
Decitabine for Injection (50mg) a therapeutic equivalent generic version of
Dacogen^® (Decitabine for Injection) in the US market on July 11, 2013,
following the approval by the United States Food & Drug Administration (USFDA)
of Dr. Reddy’s ANDA for Decitabine for Injection.
The Dacogen^® brand has U.S. sales of approximately $260 Million MAT for the
most recent twelve months ending in July 2013 according to IMS Health*.
Dr. Reddy’s Decitabine for Injection 50 mg is available as a single dose vial.
This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com
Dacogen^® is a registered trademark used by Eisai Inc. under license from
Astex Pharmaceuticals, Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT July 2013
Dr. Reddy’s Laboratories
S Rajan, +91-40- 49002445
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
Saunak Savla, +91-40-49002135
Milan Kalawadia (USA), +1 908-203-4931
Press spacebar to pause and continue. Press esc to stop.